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The vascular endothelial growth factor receptor-2 (VEGFR-2) is a tyrosine kinase receptor involved in the growth anddifferentiation
of endothelial cells that are implicated in tumor-associated angiogenesis. In this study, novel 1-aryl-3-[4-(thieno[3,2-d]pyrimidin-4-
yloxy)phenyl]ureas were synthesized and evaluated for the VEGFR-2 tyrosine kinase inhibition.Three of these compounds showed
good VEGFR-2 inhibition presenting low IC
50
values (150–199 nM) in enzymatic assays, showing also a significant proliferation
inhibition of VEGF-stimulated human umbilical vein endothelial cells (HUVECs) at low concentrations (0.5–1𝜇M), using the
Bromodeoxyuridine (BrdU) assay, not affecting cell viability.The determination of the total and phosphorylated (active) VEGFR-2
was performed by western blot, and it was possible to conclude that the compounds significantly inhibit the phosphorylation of
the receptor at 1 𝜇Mpointing to their antiproliferative mechanism of action in HUVECs.Themolecular rationale for inhibiting the
tyrosine kinase domain of VEGFR-2 was also performed and discussed using molecular docking studies.
1. Introduction
Angiogenesis is the process of new blood vessel formation
from preexisting vascular networks by capillary sprouting [1]
and plays an important role in the pathogenesis of several
disorders including cancer, vasculoproliferative ocular disor-
ders, and rheumatoid arthritis [2]. A key regulatory pathway
of angiogenesis is mediated by the vascular endothelial
growth factor (VEGF), involved in the vascular permeability
and an inducer of endothelial cell proliferation, migration,
and survival [3], and its cell membrane tyrosine kinase recep-
tor VEGFR-2 (also known as KDR) [4]. Upon ligand binding,
VEGFR-2 undergoes autophosphorylation, triggering signal-
ing pathways leading to endothelial cell proliferation and
subsequent angiogenesis. Small molecule inhibitors act by
competing with ATP for its binding site of the VEGFR-2
intracellular tyrosine kinase domain, thereby preventing the
signaling pathways that lead to angiogenesis [5]. Several small
molecule VEGFR-2 inhibitors have emerged as promising
antiangiogenic agents for possible treatment against a wide
variety of cancers (Figure 1). Sunitinib was approved for the
treatment of renal cell carcinoma and gastrointestinal stromal
tumor, and Sorafenib was approved for the treatment of
primary kidney cancer and hepatocellular carcinoma [6].
Recently, two new VEGFR-2 inhibitors have been approved
for the treatment of advanced renal cell carcinoma: axitinib
[7] and pazopanib [8]. A number of thienopyridines and
thienopyrimidines ureas have also shown potent VEGFR-2
inhibition activity [9, 10] including arylether derivatives [11–
13].
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Figure 1: Competitive inhibitors of VEGFR-2 in clinical use against several cancers: sunitinib (Sutent, C. P. Pharmaceuticals International,
NY, USA), soranefib (Nexavar, Bayer, Germany), axitinib (Inlyta, Pfizer), and pazopanib (Votrient, GlaxoSmithKline).
In this report, we describe an ongoing effort to develop
novel small molecules as VEGFR-2 inhibitors, based on
the aryletherthieno[3,2-d]pyrimidine arylurea scaffold. The
synthesis of the compounds and the VEGFR-2 tyrosine
kinase phosphorylation inhibition evaluation using either
enzymatic or cellular assays including the determination of
the total and of the phosphorylated VEGFR-2 by western blot
were performed. The probable binding mode of the 1-aryl-
3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas with the
receptor using docking studies is also presented and dis-
cussed.
2. Materials and Methods
2.1. Synthesis. Melting points (∘C) were determined in a
Stuart SMP3 and are uncorrected. 1H and 13C NMR spectra
were recorded on a Varian Unity Plus at 300 and 75.4MHz,
respectively, or on a Bruker Avance III at 400 and 100.6MHz,
respectively. Two-dimensional 1H-13C correlations were per-
formed to attribute some signals. Mass spectra (MS) EI-TOF
or ESI-TOF and HRMS on the M+, [M + H]+ or on [M +
Na]+, were performed by the mass spectrometry service of
the University of Vigo, C.A.C.T.I., Spain.
The reactions were monitored by thin layer chromatog-
raphy (TLC) using Macherey-Nagel precoated aluminium
silica gel 60 sheets (0.20mm) with UV
254
indicator. Column
chromatography was performed on Panreac, silica gel 60,
230–400 mesh.
2.1.1. General Procedure for the Synthesis of Compounds 1a
and 1b. In a flask with 5mL of DMF, thienopyrimidine (1
equiv.), 4-aminophenol (1 equiv.), and K
2
CO
3
(4 equiv.) were
heated at 140∘C for 2 h. After cooling, water (5mL) and ethyl
acetate (5mL) were added. The phases were separated, and
the aqueous phase was extracted with more ethyl acetate (2
× 5mL). The organic phase was dried (MgSO
4
) and filtered.
The solvent was evaporated under reduced pressure giving a
solid which was submitted to column chromatography.
4-(Thieno[3,2-d]pyrimidin-4-yloxy)aniline (1a). 4-Chlorothi-
eno[3,2-d]pyrimidine (242mg, 1.42mmol) and 4-amino-
phenol (155mg, 1.42mmol) were heated, and the reaction
mixture was treated according to the general procedure.
Column chromatography using ethyl acetate gave compound
1a as a yellow solid (290mg, 91%), m.p. 115.8–116.5∘C. 1H
NMR (300MHz, DMSO-𝑑
6
): 𝛿 5.15 (s, 2H, NH
2
), 6.60 (d, 𝐽
= 9.0Hz, 2H, 2 and 6-H), 6.95 (d, 𝐽 = 9.0Hz, 2H, 3 and 5-H),
7.62 (d, 𝐽 = 5.6Hz, 1H, HetAr), 8.40 (d, 𝐽 = 5.6Hz, 1H, HetAr),
8.66 (s, 1H, 2󸀠-H) ppm. 13C NMR (75.4MHz, DMSO-𝑑
6
): 𝛿
114.2 (2 and 6-CH), 116.6 (C), 122.3 (3 and 5-CH), 124.1 (CH),
137.1 (CH), 141.7 (C), 146.9 (C), 154.2 (2󸀠-CH), 162.9 (C), 164.3
(C) ppm.MS (EI-TOF)𝑚/𝑧 (%): 243.05 (M+, 100)HRMS (EI-
TOF): calcd for C
12
H
9
N
3
OS [M+] 243.0466, found 243.0467.
4-(7-Methylthieno[3,2-d]pyrimidin-4-yloxy)aniline (1b). 4-
Chloro-7-methylthieno[3,2-d]pyrimidine (242mg, 1.31m
mol) and 4-aminophenol (143mg, 1.31mmol) were heated,
and the reaction mixture was treated according to the
general procedure. Column chromatography using ethyl
acetate gave compound 1b as a yellow solid (310mg, 92%),
m.p. 167.8–168.6∘C. 1H NMR (300MHz, DMSO-𝑑
6
): 𝛿 2.40
(s, 3H, CH
3
), 5.13 (s, 2H, NH
2
), 6.61 (d, 𝐽 = 9.0Hz, 2H, 2 and
6-H), 6.93 (d, 𝐽 = 9.0Hz, 2H, 3 and 5-H), 8.01 (s, 1H, 6󸀠-H),
8.67 (s, 1H, 2󸀠-H) ppm. 13C NMR (75.4MHz, DMSO-𝑑
6
): 𝛿
12.5 (CH
3
), 114.2 (2 and 6-CH), 116.8 (C), 122.3 (3 and 5-CH),
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131.4 (6󸀠-CH), 132.6 (C), 141.7 (C), 146.8 (C), 153.9 (2󸀠-CH),
161.8 (C), 164.3 (C) ppm. MS (EI-TOF)𝑚/𝑧 (%): 257.06 (M+,
100) HRMS (EI-TOF): calcd for C
13
H
11
N
3
OS [M+] 257.0623,
found 257.0621.
2.1.2. General Procedure for the Synthesis of 1,3-Diarylureas
2a–f. Compounds 1a or 1b and different arylisocyanates (1
equiv.) in 6mL CH
2
Cl
2
: THF (1 : 1) were left stirring at room
temperature for 16 h. If a precipitate does not come out
after this time, hexane (3–5mL) is added to the mixture to
precipitate the product. This was filtered under vacuum to
give the corresponding 1,3-diarylureas.
1-Phenyl-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]urea
(2a). From compound 1a (100mg, 0.410mmol), and
phenylisocyanate (0.0400mL, 0.410mmol) compound 2a
was isolated as a white solid (117mg, 79%), m.p. 237.3–
238.7∘C. 1H NMR (400MHz, DMSO-𝑑
6
): 𝛿 6.95–6.99 (m,
1H, Ar-H), 7.24–7.30 (m, 4H, Ar-H), 7.45–7.47 (m, 2H, 2 ×
Ar-H), 7.54 (d, 𝐽 = 9.0Hz, 2H, 2 × Ar-H), 7.65 (d, 𝐽 = 5.2Hz,
1H, HetAr), 8.45 (d, 𝐽 = 5.2Hz, 1H, HetAr), 8.68 (s, 1H,
NH), 8.69 (s, 1H, 2󸀠󸀠󸀠-H), 8.78 (s, 1H, NH) ppm. 13C NMR
(100.6MHz, DMSO-𝑑
6
): 𝛿 116.8 (C), 118.2 (2 × CH), 119.2
(2 × CH), 121.8 (CH), 122.3 (2 × CH), 124.2 (CH), 128.8 (2
× CH), 137.2 (CH), 137.6 (C), 139.6 (C), 146.0 (C), 152.6 (C),
154.1 (2󸀠󸀠󸀠-CH), 163.0 (C), 163.8 (C) ppm. MS (ESI-TOF)𝑚/𝑧
(%): 363.09 ([M + H]+, 100) HRMS (ESI-TOF): calcd for
C
19
H
15
N
4
O
2
S [M + H]+ 363.0910, found 363.0909.
1-(4-Methoxyphenyl)-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)
phenyl]urea (2b). From compound 1a (100mg, 0.410mmol),
and 4-methoxyphenylisocyanate (0.0500mL, 0.410mmol)
compound 2b was isolated as a white solid (145mg, 90%),
m.p. 247.2–248.3∘C. 1H NMR (400MHz, DMSO-𝑑
6
): 𝛿 3.71
(s, 3H, OCH
3
), 6.86 (d, 𝐽 = 9.0Hz, 2H, 3󸀠 and 5󸀠-H), 7.23
(d, 𝐽 = 9.0Hz, 2H, 2 × Ar-H), 7.36 (d, 𝐽 = 9.0Hz, 2H, 2󸀠
and 6󸀠-H), 7.53 (d, 𝐽 = 9.0Hz, 2H, 2 × Ar-H), 7.65 (d, 𝐽 =
5.6Hz, 1H, HetAr), 8.44 (d, 𝐽 = 5.6Hz, 1H, HetAr), 8.50
(s, 1H, NH), 8.69 (s, 1H, 2󸀠󸀠󸀠-H), 8.70 (s, 1H, NH) ppm. 13C
NMR (100.6MHz, DMSO-𝑑
6
): 𝛿 55.1 (OCH
3
), 114.0 (3󸀠 and
5󸀠-CH), 116.8 (C), 119.1 (2 × CH), 120.1 (2󸀠 and 6󸀠-CH), 122.3
(2 × CH), 124.2 (CH), 132.7 (C), 137.2 (CH), 137.8 (C), 145.9
(C), 152.8 (C), 154.1 (2󸀠󸀠󸀠-CH), 154.5 (C), 163.0 (C), 163.8 (C)
ppm. MS (ESI-TOF) 𝑚/𝑧 (%): 393.08 ([M+H]+, 39) HRMS
(ESI-TOF): calcd for C
20
H
17
N
4
O
3
S [M+H]+ 393.1016, found
393.1026.
1-(4-Cyanophenyl)-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)
phenyl]urea (2c). From compound 1a (100mg, 0.410mmol)
and 4-cyanophenylisocyanate (59.0mg, 0.410mmol), com-
pound 2c was isolated as a white solid (111mg, 70%), m.p.
245.5–247.2∘C. 1H RMN (300MHz, DMSO-𝑑
6
): 𝛿 7.26 (d, 𝐽
= 9.2Hz, 2H, 2 × Ar-H), 7.55 (d, 𝐽 = 9.2Hz, 2H, 2 × Ar-H),
7.62–7.66 (m, 3H, 2󸀠 and 6󸀠-H and HetAr), 7.73 (d, 𝐽 = 9.2Hz,
2H, 3󸀠 and 5󸀠-H), 8.45 (d, 𝐽 = 5.2Hz, 1H, HetAr), 8.69 (s,
1H, 2󸀠󸀠󸀠-H), 8.99 (s, 1H, NH), 9.24 (s, 1H, NH) ppm. 13C
NMR (75.4MHz, DMSO-𝑑
6
): 𝛿 103.3 (C), 116.8 (C), 118.0
(2󸀠 and 6󸀠-CH), 119.3 (C), 119.7 (2 × CH), 122.4 (2 × CH),
124.3 (CH), 133.3 (3󸀠 and 5󸀠-CH), 137.0 (C), 137.2 (CH), 144.2
(C), 146.5 (C), 152.2 (C), 154.1 (2󸀠󸀠󸀠-CH), 163.0 (C), 163.8 (C)
ppm. MS (ESI-TOF)𝑚/𝑧 (%): 388.09 ([M +H]+, 100) HRMS
(ESI-TOF): calcd for C
20
H
13
N
5
O
2
S [M + H]+ 388.0863,
found 388.0861.
1-Phenyl-3-[4-(7-Methylthieno[3,2-d]pyrimidin-4-yloxy)phe-
nyl]urea (2d). From compound 1b (100mg, 0.389mmol)
and phenylisocyanate (0.0400mL, 0.389mmol), compound
2d was isolated as a white solid (121mg, 83%), m.p. 285.7–
287.3∘C. 1H NMR (400MHz, DMSO-𝑑
6
): 𝛿 2.43 (s, 3H,
CH
3
), 6.96 (m, 1H, Ar-H), 7.23–7.29 (m, 4H, Ar-H), 7.46 (m,
2H, 2 × Ar-H), 7.53 (d, 𝐽 = 9.2Hz, 2H, 2 × Ar-H), 8.10 (s, 1H,
6
󸀠󸀠󸀠-H), 8.70 (s, 1H, NH), 8.71 (s, 1H, 2󸀠󸀠󸀠-H), 8.78 (s, 1H, NH)
ppm. 13C NMR (100.6MHz, DMSO-𝑑
6
): 𝛿 12.5 (CH
3
), 116.9
(C), 118.2 (2 × CH), 119.2 (2 × CH), 121.8 (C), 122.3 (2 × CH),
128.8 (2 × CH), 131.5 (6󸀠󸀠󸀠-CH), 132.7 (C), 137.6 (C), 139.6
(C), 146.1 (C), 152.6 (C), 153.9 (2󸀠󸀠󸀠-CH), 161.9 (C), 163.9 (C)
ppm. MS (ESI-TOF)𝑚/𝑧 (%): 377.10 ([M + H]+, 100) HRMS
(ESI-TOF): calcd for C
20
H
17
N
4
O
2
S [M +H]+ 377.1067, found
377.1064.
1-(4-Methoxyphenyl)-3-[4-(7-methylthieno[3,2-d]pyrimidin-
4-yloxy)phenyl]urea (2e). From compound 1b (100mg,
0.389mmol) and 4-methoxyphenylisocyanate (0.0500mL,
0.389mmol), compound 2e was isolated as a white solid
(131mg, 83%), m.p. 248.4–249.6∘C. 1H NMR (400MHz,
DMSO-𝑑
6
): 𝛿 2.43 (s, 3H, CH
3
), 3.71 (s, 3H, OCH
3
), 6.86
(d, 𝐽 = 9.2Hz, 2H, 3󸀠 and 5󸀠-H), 7.22 (d, 𝐽 = 9.2Hz, 2H, 3󸀠󸀠
and 5󸀠󸀠-H), 7.36 (d, 𝐽 = 9.2Hz, 2H, 2󸀠 and 6󸀠-H), 7.52 (d, 𝐽 =
9.2Hz, 2H, 2󸀠󸀠 and 6󸀠󸀠-H), 8.06 (s, 1H, 6󸀠󸀠󸀠-H), 8.49 (s, 1H,
NH), 8.69 (s, 1H, NH), 8.70 (s, 1H, 2󸀠󸀠󸀠-H) ppm. 13C NMR
(100.6MHz, DMSO-𝑑
6
): 𝛿 12.5 (CH
3
), 55.2 (OCH
3
), 114.0
(3󸀠 and 5󸀠-CH), 116.9 (C), 119.1 (2󸀠󸀠 and 6󸀠󸀠-CH), 120.1 (2󸀠 and
6󸀠-CH), 122.2 (3󸀠󸀠 and 5󸀠󸀠-CH), 131.5 (6󸀠󸀠󸀠-CH), 132.7 (C),
137.8 (C), 146.0 (C), 152.8 (C), 153.9 (2󸀠󸀠󸀠-CH), 154.5 (C), 161.9
(C), 163.9 (C) ppm. MS (ESI-TOF) 𝑚/𝑧 (%): 407.12 ([M +
H]+, 100) HRMS (ESI-TOF): calcd for C
21
H
19
N
4
O
3
S [M +
H]+ 407.1172, found 407.1182.
1-(4-Cyanophenyl)-3-[4-(7-methylthieno[3,2-d]pyrimidin-4-
yloxy)phenyl]urea (2f ). From compound 1b (100mg, 0.389
mmol) and 4-cyanophenylisocyanate (56.0mg, 0.389mmol),
compound 2f was isolated as a white solid (128mg, 82%),
m.p. 246.7–248.2∘C. 1H NMR (400MHz, DMSO-𝑑
6
): 𝛿 2.42
(s, 3H, CH
3
), 7.25 (d, 𝐽 = 9.2Hz, 2H, 3󸀠󸀠 and 5󸀠󸀠-H), 7.54 (d,
𝐽 = 9.2Hz, 2H, 2󸀠󸀠 and 6󸀠󸀠-H), 7.64 (d, 𝐽 = 9.2Hz, 2H, 2󸀠
and 6󸀠-H), 7.72 (d, 𝐽 = 9.2Hz, 2H, 3󸀠 and 5󸀠-H), 8.06 (s, 1H,
6
󸀠󸀠󸀠-H), 8.70 (s, 1H, 2󸀠󸀠󸀠-H), 8.97 (s, 1H, NH), 9.23 (s, 1H, NH)
ppm. 13C NMR (100.6MHz, DMSO-𝑑
6
): 𝛿 12.5 (CH
3
), 103.3
(C), 117.0 (C), 118.1 (2󸀠 and 6󸀠-CH), 119.3 (C), 119.7 (2󸀠󸀠 and
6
󸀠󸀠-CH), 122.4 (3󸀠󸀠 and 5󸀠󸀠-CH), 131.5 (6󸀠󸀠󸀠-CH), 132.7 (C),
133.3 (3󸀠 and 5󸀠-CH), 137.0 (C), 144.2 (C), 146.6 (C), 152.2
(C), 153.9 (2󸀠󸀠󸀠-CH), 162.0 (C), 163.8 (C) ppm. MS (ESI-TOF)
𝑚/𝑧 (%): 402.10 ([M + H]+, 100) HRMS (ESI-TOF): calcd for
C
21
H
16
N
5
O
2
S [M + H]+ 402.1019, found 402.1029.
2.2. VEGFR-2 Enzymatic Inhibition Assay. The compounds
were assessed for VEGFR-2 inhibition activity using the 𝑍󸀠-
LYTE-Tyr1 Peptide assay kit (according to the procedures
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Scheme 1: Synthesis of 1-aryl-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas 2a–2f. The yields are presented as % of pure compounds.
recommended by the manufacturer Invitrogen, Cat. PV3190)
[14]. Briefly, assays were performed in a total of 20𝜇L in
384-well plates using fluorescence resonance energy transfer
technology. A Tyr1 substrate (coumarin-fluorescein double-
labeled peptide) at 1.0𝜇Mwas incubated for 1 h with 4 𝜇g/mL
VEGFR-2, 10 𝜇MATP, and inhibitors at room temperature in
50mM Hepes/Na (pH 7.5), 10mM MgCl
2
, 2.0mM MnCl
2
,
2.5mM DTT, 0.10mM orthovanadate, and 0.01% bovine
serum albumin. The wells were incubated at 25∘C for 1 hour
and 5.0 𝜇L of the development reagent was added to each
well. After a second incubation of 1 hour, a stop reagent
was added to each well. Using a Biotek FLX800 microplate,
the fluorescence was read at 445 nm and 520 nm (excitation
400 nm), and Gen5 Software was used for data analysis.
The validation assay was performed using Staurosporine
that presented a IC
50
value 6 nM that compares to the one
reported in the literature (IC
50
7 nM) [14].
2.3. Cell Culture Experiments Using HUVECs
2.3.1. Cell Cultures. Human umbilical vein endothelial cells
(HUVECs) were obtained from the ScienceCell Research
Labs (San Diego, CA, USA), HUVECs were seeded on
plates coated with 0.2% gelatin (Sigma-Aldrich, Sintra, Por-
tugal) and cultured in M199 medium (Sigma-Aldrich, Sin-
tra, Portugal) supplemented with 20% fetal bovine serum
(FBS) (Invitrogen Life Technologies, Scotland, UK), 1% peni-
cillin/streptomycin (Invitrogen Life Technologies), 0.01%
heparin (Sigma-Aldrich), and 30mg/mL endothelial cell
growth supplement (Biomedical Technologies Inc., MA,
USA) and maintained at 37∘C in a humidified 5% carbon
dioxide atmosphere. Cells were kept between passages 3 and
8 for every experiment. The test compounds were dissolved
in DMSO and added to cell cultures at a concentration of
0.1–10 𝜇M. Incubations were performed for 24 h in medium
supplemented with 2% FBS, 1% penicillin/streptomycin, and
60 ng/mL of the vascular endothelial growth factor (Sigma-
Aldrich, Sintra, Portugal). Control cells were incubated with
vehicle (DMSO at 0.1% in every culture).
2.3.2. MTS Toxicity Assay. HUVECs (2 × 105 cells/mL)
were allowed to grow for 24 h and then incubated with the
test compounds at a range concentration between 0.1 and
10 𝜇M or control (0.1% DMSO) for 24 h. After the incubation
period, cells were washed and their viability was assessed
using Cell Titer 96 Aqueous ONE Solution Reagent MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium] colorimetric assay (Pro-
mega,Madison,USA), according to the instructions provided
by the manufacturer and as previously described [15].
Optical density was measured at 492 nm. Three independent
experiments were performed, and the results were expressed
as mean ± SEM.
2.3.3. BrdU Incorporation Assay. HUVECs (6 × 104 cells/mL)
were grown during 24 h and then were incubated with
the compounds at 0.1–10 𝜇M or control (0.1% DMSO) for
24 h. Cells were also incubated with 5󸀠-bromodeoxyuridine
(BrdU), a thymidine analogue which incorporates into DNA
of dividing cells. After incubation with BrdU solution at a
final concentration of 0.01mM during the treatment period,
the optical density of proliferating cells (positive for BrdU)
after ELISA assay using anti-BrdU-specific antibodies (Roche
Diagnostics, Mannheim, Germany) was evaluated at the
microplate reader according to the manufacturer’s instruc-
tions and as previously reported [16]. The results are given
as percentage versus control group (100%).
2.3.4. Cell Apoptosis. HUVECs (6× 104 cells/mL)were grown
for 24 h on glass coverslips and incubated with different
concentrations (0.1–1𝜇M) of the tested compounds. TUNEL
assay was performed using the In Situ Cell Death Detection
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Figure 2: (a) Cell viability was evaluated in HUVECs upon treatment with 2a, 2b, and 2c at 0.10, 0.50, 1.0, 5.0 and 10 𝜇M, or untreated
(control, 0.1% DMSO) using MTS assay. (b) Cell proliferation was assessed by BrdU incorporation assay. Bars represent the percentage of
proliferating cells when compared to control group, after incubation with anti-BrdU antibody by ELISA assay. (c) Apoptosis was assessed
in HUVECs by TUNEL assay using 2a, 2b, and 2c at 0.1, 0.5, and 1 𝜇M. Bars represent the percentage of apoptotic cells evaluated by the
ratio between TUNEL-stained cells and DAPI-stained nuclei in every culture. Results are expressed as mean ± SEM of three independent
experiments (5 < 𝑛 < 10). ∗𝑃 < 0.05 versus control.
kit (Roche Diagnostics, Mannheim, Germany), according to
the manufacturer’s instruction and as previously reported
[16]. Immunofluorescence was visualized under a fluores-
cence microscope (Olympus, BH-2, UK). The percentage
of stained cells was evaluated by counting the cells stained
with TUNEL (apoptotic cells) divided by the total number
of nuclei counterstained with DAPI (Invitrogen, CA, USA)
at a 200x magnification field. One thousand nuclei were
evaluated. Results were expressed as percentage of control
(100%).
2.3.5. Western Blotting Analyses. Proteins were isolated from
HUVEC lysates using RIPA (Chemicon International, CA,
USA). Proteins were quantified using a spectrophotometer
(Jenway, 6405 UV/vis, Essex, UK), and 20𝜇g of protein
were subjected to 8% SDS-PAGE with a 5% stacking gel.
After electrophoresis, proteins were blotted into a Hybond
nitrocellulose membrane (Amersham, Arlington, VA, USA).
Immunodetection for total VEGFR-2 (1 : 1000; Cell Signaling,
MA, USA), phosphorylated (activated) VEGFR-2 (1 : 750;
Santa Cruz Biotechnology, CA, USA), and 𝛽-actin (1 : 3000;
Abcam, Cambridge, UK) was accomplished with enhanced
chemiluminescence (ECL kit, Amersham, Arlington, USA).
The phosphorylated antibody recognizes Tyr951 kinase insert
domain, a major site of VEGFR-2 phosphorylation partic-
ularly involved in angiogenic processes. The relative inten-
sity of each protein blotting analysis was measured using
a computerized software program (Bio-Rad, CA, USA), and
the expression of activated and total VEGFR-2 were nor-
malized with total VEGFR-2 and 𝛽-actin bands, respectively,
to compare the expression of proteins in different treatment
groups.
2.3.6. Statistical Analyses. All experiments were performed
at least in three independent experiments. Quantifications
are expressed as mean ± SEM. Statistical significance of
difference between the distinct groups was evaluated by anal-
ysis of variance (ANOVA) followed by the Bonferroni test.
A difference between experimental groups was considered
significant with a confidence interval of 95%, whenever 𝑃 <
0.05.
2.4. Docking Simulations Using AutoDock4. A VEGFR-2
crystal structure (PDB: 2XIR) was extracted from the Protein
Data Bank (PDB) (http://www.rcsb.org/). The cocrystallized
ligand was extracted from the PDB file, and AutoDockTools
was used to assign polar hydrogens and Gasteiger charges to
the compounds [17]. AutoGrid4 was used to create affinity
gridmaps for all the atom types.The affinity grids enclosed an
area of 100 × 100 × 100 with 0.375 A˚ spacing, centered on the
coordinates 𝑥 = 86.3, 𝑦 = 51.2, and 𝑧 = 48.3. AutoDock4
(version 4.1) with the Lamarckian genetic algorithm was
used with the following docking parameters: 100 docking
runs, population size of 200, random starting position and
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Table 1: Results of the VEGFR2 enzymatic inhibition assay using
compounds 2a–f.
Compounds VEGFR-2IC50 (𝜇M)
a
2a 0.199
2b 0.188
2c 0.150
2d >100
2e >100
2f >100
aEach IC50 determination is a result of four separate determinations.
conformation, translation step ranges of 2.0 A˚, mutation rate
of 0.02, crossover rate of 0.8, local search rate of 0.06, and 2.5
million energy evaluations [17]. The entire virtual screening
experiment was performed on a cluster of 8 Intel Dual-Core
2.8GHz computers using MOLA software [18]. Inhibition
constants (𝐾
𝑖
) for all ligands were calculated by AutoDock4
as follows:𝐾
𝑖
= exp((Δ𝐺∗1000)/(𝑅cal∗TK)), whereΔ𝐺 is the
binding energy, 𝑅cal is 1.98719, and TK is 298.15. All figures
with structure representations were prepared using PyMOL
software [19].
3. Results and Discussion
3.1. Synthesis. We were able to promote the regioselective
attack of the hydroxyl group of the 4-aminophenol in the
chlorine nucleophilic displacement of two commercial 4-
chlorinated thieno[3,2-d]pyrimidines, using stoichiometric
amounts of the reagents, in the synthesis of the aminated
compounds 1a and 1b in excellent yields (Scheme 1). This
regioselectivity constitutes an important achievement that
avoids the reaction of 4-nitrophenols followed by reduction
of the nitro compounds to the corresponding amino com-
pounds, as often described in the literature [12, 13]. With
4-aminophenol as a reagent, it is possible to use DMF as
solvent and heat only at 140∘C instead of diphenylether at
180∘C which is needed for the nucleophilic displacement of
the chlorine using 4-nitrophenol. The amino compounds 1a
and 1b, obtained in one step, were then reacted with different
arylisocyanates to give the corresponding new 1-aryl-3-[4-
(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas 2a–2f in high
yields (Scheme 1). Compounds 1a, b, and 2a–2f were fully
characterized by m.p., 1H, 13C NMR, and mass spectrometry
including HRMS.
3.2. Biological Evaluation
3.2.1. Enzymatic Assays. The synthesized thieno[3,2-d]pyr-
imidine ureas 2a–f were evaluated for their ability to interact
with the VEGFR2 tyrosine kinase domain (Table 1), using
an enzymatic FRET-based assay. Compounds 2a, 2b, and 2c
displayed the highest inhibition with IC
50
values of 199, 188,
and 150 nM, respectively. The presence of a methoxy group
in the para position of the phenyl ring (2b) did not show a
significant increase in VEGFR-2 inhibition activity relative to
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Figure 3: (a) Evaluation of phosphorylated and total VEGFR-2
expression in HUVECs after incubation with compounds 2a, 2b,
and 2c by western blotting. Representative bands obtained after
immunostaining are shown. (b) Quantification of densitometry
and mean relative intensity by comparison of the relative intensity
of activated VEGFR-2 after normalization with total VEGFR-2
intensity. Data presented as mean ± SEM of two independent
experiments. ∗𝑃 < 0.05 versus control.
2a, while the presence of a nitrile group in the same position
(2c) promoted a small increase in VEGFR-2 inhibition
activity. These findings appear to suggest that the presence of
small substituents in the para position of the phenyl group
will not have a significant effect on VEGFR-2 potency of the
compounds. When a methyl group is present in position 7
of the thieno[3,2-d]pyrimidine moiety (compounds 2d–f),
no VEGFR-2 inhibition activity was observed. This finding
indicates that substitutions on the mentioned position are
not favorable for this series of thieno[3,2-d]pyrimidine ureas,
when considering VEGFR-2 inhibition activity.
3.2.2. Cellular Assays. The best compounds in enzymatic
assays (2a, 2b, and 2c) were studied at cellular level. Cell
cytotoxicity was first analyzed by MTS assay in the HUVEC
cultures upon treatment with 0.10–10 𝜇M of compounds 2a–
c (Figure 2(a)). Viability of HUVEC decreased at the highest
concentration of 2c (1.96 ± 0.02 O.D.) and at concentrations
of 5.0 and 10 𝜇M for 2a (2.00±0.06O.D. and 1.99±0.03O.D.,
resp.) and for 2b (1.84±0.05O.D. and 1.82±0.04O.D., resp.)
versus control (2.33 ± 0.06 O.D.).
Then, the ability of compounds 2a–c to inhibit VEGF-
stimulated proliferation of HUVECs was evaluated using the
BrdU incorporation assay (Figure 2(b)). Inhibition of the
VEGFR-2 activity was strongly reflected at the cellular level,
with all the three compounds showing a statistical significant
inhibition activity against VEGF-stimulated HUVEC prolif-
eration at 0.5𝜇M (15.2 ± 2.7% for 2a; 12.8 ± 2.4% for 2b,
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Figure 4: (a) Superimposition of the docking poses at the VEGFR-2 kinase domain for compounds: 2a (cyan), 2b (green) and 2c (orange).
(b) Surface representation of the VEGFR-2 kinase hinge with the docking poses of compounds 2c (orange)and 2f (light grey). H-bonds are
depicted in dashed yellow lines (distances between 2.9 and 3.3 A˚) and hydrophobic interactions are depicted in dashed white lines (distances
between 3.5 and 4.0 A˚). Important residues are drawn in sticks. Figures were prepared using PyMOL [19].
and 14.7 ± 1.7% for 2c) when comparing to control, which
is consider to be 100.00 ± 2.8%.
The number of proliferating HUVECs decreased in a
dose-dependent manner (Figure 2(b)).
Interestingly, incubation of HUVECs with compounds
2a, 2b, and 2c for 24 h with concentrations 0.1, 0.5, and
1 𝜇M (due to cytotoxic effect for higher concentrations,
Figure 2(a)) using the TUNEL assay resulted in an increase
in apoptosis, reaching statistical significance only for 2a at
the highest concentration tested (32.8 ± 1.23% increase)
comparing with untreated cells (Figure 2(c)).
To investigate the cellular inhibition of VEGFR-2 by the
compounds in HUVEC cultures, immunoblotting assays for
total and phosphorylated (active) VEGFR-2 were performed
(Figure 3(a)). As illustrated in Figure 3(b), incubation with
compounds 2a and 2b significantly decrease the formation of
the active form of the receptor at 1 𝜇M concentration, when
comparing with the expression of VEGFR-2 (∗𝑃 < 0.05).
Compound 2c did not significantly inhibit the activation
of the VEGFR-2, although a dose-dependent decrease was
observed.
VEGF signaling pathway through the VEGFR-2 acti-
vation displays a crucial role in endothelial cells, namely,
survival, proliferation, invasion, and apoptosis. Our data sug-
gest that compounds 2a–c exert direct actions in HUVECs
by inhibiting their growth mainly at 0.5 and 1 𝜇M, slightly
increasing the percentage of apoptotic cells without cytotoxic
effects at the same range of concentrations. The referred
cellular-based results are triggered by the inhibition of the
phosphorylation (activation) of the VEGFR-2, which is over-
expressed in several pathological conditions, such as cancer.
3.3. Molecular Modelling Studies. To better understand the
molecular basis of compounds 2 observed VEGFR-2 inhibi-
tion activity, docking simulations using AutoDock4 [17] were
carried out against the VEGFR-2 kinase domain (PDB code
2XIR).
Figure 4(a) displays the superimposition of the best
docked poses obtained for the most potent thieno[3,2-
d]pyrimidine derivatives 2a–c. They present similar docking
poses, with the binding conformation stabilized mainly by
the formation of a network of four H-bonds. The two N–
H of the urea group form two H-bonds with the Glu885
carboxyl group, while the C=O bond of the urea group forms
a third H-bond with the backbone N–H of Asp1046. These
H-bonds are similar to the ones observed with other known
VEGFR-2 inhibitors presenting a biphenyl urea moiety,
including the drug Soranefib (Figure 1). A fourth H-bond is
predicted between the N atom in position 4 of the thieno[3,2-
d]pyrimidine moiety and the backbone N–H of Cys919.
The terminal aryl group is positioned in a hydropho-
bic region formed by several hydrophobic residues (Ile888,
Leu889, Ile892, Val898, Val 899, and Leu1019). From
Figure 4(a), it is clearly observed that the 4-methoxyphenyl
and 4-cyanophenyl substituents occupy part of a large
hydrophobic pocket that is able to accommodate them,
providing an explanation for compounds 2b and 2c being
almost equipotent to 2a that bears no substituents in the
phenyl ring. Substitutions of hydrophobic groups in ortho
or meta positions of the phenyl ring will probably be worth
exploring for synthesis of even more potent compounds in
this series.
The lack of inhibition by compounds 2d–f for VEGFR-
2 was analysed by superimposing the docked pose of
compound 2c (the most potent in the enzymatic assays,
150 nM) and the corresponding 7-methylated compound
2f (Figure 4(b)). The methyl group seems to displace the
thieno[3,2-d]pyrimidine ring away from Cys919. This
displacement probably interferes with the formation of
the H-bond between the N atom in position 4 of the
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thieno[3,2-d]pyrimidine ring and the backbone N–H of
Cys919 (Figure 4(b)). These results demonstrate that this
H-bond is an absolute requirement for VEGFR-2 inhibition
potency of this thieno[3,2-d]pyrimidine series, and the
methyl group in position 7 of compounds 2d–f promotes
loss of VEGFR-2 inhibition activity by impairing H-bond
formation. We can also infer that other substitutions in
position 7 of the thieno[3,2-b]pyridine are probably not
desirable as they will also impair H-bond formation.
4. Conclusion
In conclusion, we reported the synthesis of novel 1-aryl-
3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas 2a–2f
in high yields in two steps: the regioselective nucleophilic
displacement of chlorine on two 4-chlorothieno[3,2-
d]pyrimidines using 4-aminophenol and the reaction of the
resultant 4-(thieno[3,2-d]pyrimidin-4-yloxy)anilines with
arylisocyanates. Compounds 2a–c, without the methyl group
in position 7, were shown to be the most potent VEGFR-2
inhibitors presenting IC
50
values between 150–199 nM in
enzymatic assays. The cell culture assays enable us to identify
the angiogenic steps targeted by the compounds 2a–c. In
fact, compounds were evaluated using a cell-based HUVEC
assay and showed activity at the same concentration range
(0.5–1𝜇M) without affecting cell viability, inhibiting cell
proliferation, and avoiding the formation of active VEGFR-2
specially in the case of compounds 2a and 2b, thus showing
their anti-angiogenic potential. Compound 2a increases also
apoptosis at the highest concentration tested (1 𝜇M) using the
TUNEL assay. By performing docking studies, the binding
conformation and H-bond network of the most promising
compounds 2a–c were predicted. Based on these molecular
modelling studies, several suggestions can be done for the
synthesis of even more potent compounds.
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